Equities

Bactiguard Holding AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Bactiguard Holding AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)17.40
  • Today's Change1.80 / 11.54%
  • Shares traded23.65k
  • 1 Year change-49.27%
  • Beta0.5069
Data delayed at least 15 minutes, as of Feb 27 2026 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bactiguard Holding AB is a Sweden-based company engaged in the development of solutions for preventing of device-related healthcare associated infections (HAI). Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. It consists of the noble metals: gold, palladium and silver, which reduces the adhesion of bacteria to the coated surfaces. Its product portfolio includes: BIP Foley Catherer, made from medical grade latex, and BIP Foley Catheter - Silicone, used for drainage and irrigation of the bladder; BIP Endotracheal Tube, for general anesthesia, intensive care, and emergency medicine for airway management and mechanical ventilation; and BIP Central Venous Catherer, made of polyurethane and used to administer drugs and intravenous solutions, monitor pressure and blood sampling. The Company is also present in Portugal, via a distribution agreement with Socime Medical Ltd, and Zambia.

  • Revenue in SEK (TTM)228.77m
  • Net income in SEK-7.84m
  • Incorporated2010
  • Employees153.00
  • Location
    Bactiguard Holding ABBiblioteksgatan 25STOCKHOLM 114 35SwedenSWE
  • Phone+46 84405880
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
INIFY Laboratories AB20.14m-61.42m307.97m34.00--2.35--15.29-1.13-1.130.36641.700.19282.963.12848,737.60-58.78---58.78--85.20---304.93------0.00--1,000.67--3.15------
Acarix AB7.36m-48.09m319.02m8.00--8.67--43.35-0.0427-0.04270.00650.03280.1140.16583.37---74.50-80.03-84.46-94.1984.7483.62-653.38-1,091.793.45-623.52----18.6927.6727.34------
Ortoma AB77.19m-7.52m416.18m10.00--2.6479.705.39-0.2027-0.20272.084.450.42433.9539.137,530,537.00-4.13-9.37-4.45-10.4341.26158.24-9.74-78.903.02--0.00--28.77--46.83---0.5751--
Mentice AB274.49m-43.31m431.73m121.00--3.43--1.57-1.68-1.6810.524.480.96631.603.942,095,328.00-15.25-6.64-31.60-11.9190.4084.80-15.78-8.530.845-30.100.116--6.1114.22-553.89--32.86--
Q linea AB11.10m-182.48m465.77m83.00--1.38--41.97-35.87-35.871.3117.840.04290.40062.90---70.50-76.00-101.81-93.84-15.26-145.47-1,644.30-2,820.5110.04-30.480.017--369.86114.7515.86---34.47--
Modulight Oyj75.41m-49.11m506.44m71.00--1.06--6.72-0.12-0.120.18741.050.1341-1.014.54---8.73-11.40-9.39-12.14132.06125.90-65.10-126.563.79--0.0588--72.63-6.8228.59--15.83--
Bactiguard Holding AB228.77m-7.84m540.16m153.00--1.9413.772.36-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Gentian Diagnostics ASA167.55m12.58m578.28m63.0046.702.9727.233.450.84590.845911.3513.290.72311.566.36--5.43-0.04836.25-0.05555.6447.277.51-0.07883.81--0.0866--16.0722.75-70.73--10.72--
Optomed Oyj182.36m-70.83m612.18m111.00--2.39--3.36-0.3374-0.33740.86881.120.53632.875.07154,009.00-20.83-17.19-25.75-20.6963.6064.81-38.85-34.212.03-8.910.1014--13.675.61-21.83--5.30--
BioPorto A/S52.20m-123.91m639.68m48.00--11.70--12.26-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
Nanexa AB36.15m-11.39m655.87m15.00--6.39570.3218.14-0.0724-0.07240.22550.62370.314416.225.232,409,933.00-9.90-31.63-12.96-38.7886.0296.94-31.50-218.011.51-3.210.0109--48.3972.5054.27--3.54--
Senzime AB (publ)104.02m-137.42m707.47m50.00--2.32--6.80-0.9396-0.93960.70731.940.26192.617.48---34.60-36.25-37.96-39.0233.3524.11-132.11-271.043.04-7.450.044--77.8961.95-15.74--123.16--
OssDsign AB180.16m-50.99m715.75m32.00--2.31--3.97-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
Omda AS450.83m-28.74m773.95m260.00--23.9527.501.72-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Data as of Feb 27 2026. Currency figures normalised to Bactiguard Holding AB's reporting currency: Swedish Krona SEK

Institutional shareholders

42.65%Per cent of shares held by top holders
HolderShares% Held
Nordea Investment Management ABas of 31 Dec 20243.59m11.57%
Fj�rde AP-fondenas of 31 Dec 20243.48m11.20%
Handelsbanken Fonder ABas of 31 Dec 20242.08m6.69%
AMF Fonder ABas of 31 Dec 20241.71m5.52%
Avanza Fonder ABas of 31 Dec 20241.14m3.67%
Lancelot Asset Management ABas of 31 Dec 2024500.00k1.61%
SEB Funds ABas of 30 Jan 2026438.19k1.41%
Storebrand Asset Management ASas of 31 Jan 2026215.35k0.69%
Skandia Investment Management ABas of 28 Nov 202565.21k0.21%
Deka Investment GmbHas of 30 Sep 202524.00k0.08%
More ▼
Data from 31 Dec 2024 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.